View More Recent Stories

Mar 15, 2023 07:35PM Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023
Mar 1, 2023 08:00AM Celcuity to Participate in Cowen's 43rd Annual Health Care Conference
Feb 16, 2023 08:03AM Celcuity (CELC) Presents Preclinical Data on Therapeutic Effects of Gedatolisib
Feb 16, 2023 08:00AM Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Prostate Cancer at ASCO GU Cancers Symposium
Dec 12, 2022 07:30AM Celcuity Closes $100 Million Private Placement
Dec 9, 2022 08:42AM Celcuity (CELC) Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
Dec 9, 2022 08:40AM Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Patients with Advanced Breast Cancer at the 2022 San Antonio Breast Cancer Symposium
Dec 7, 2022 04:00PM Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-1 Clinical Trial of Gedatolisib for the Treatment of HR+/HER2- Advanced Breast Cancer
Nov 22, 2022 07:30AM Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium
Nov 10, 2022 04:30PM Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference
Nov 10, 2022 04:00PM Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 3, 2022 08:50AM Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call
Sep 14, 2022 09:02AM Celcuity (CELC) Appoints Polly Murphy to its Board
Sep 14, 2022 09:00AM Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors
View More Recent Stories